Next Article in Journal
Study on New Bolted T-Stub Connection with Inserted Plates under Axial and Cyclic Loads
Next Article in Special Issue
Host-Directed Therapies and Anti-Virulence Compounds to Address Anti-Microbial Resistant Tuberculosis Infection
Previous Article in Journal
Predictive Voltage Control: Empowering Domestic Customers With a Key Role in the Active Management of LV Networks
Previous Article in Special Issue
TB Elimination Requires Discovery and Development of Transformational Agents
Open AccessFeature PaperReview

Update on TB Vaccine Pipeline

Grupo de Genética de Micobacterias, Microbiología, Facultad de Medicina Universidad de Zaragoza, 50009 Zaragoza, Spain
CIBERES Enfermedades Respiratorias, Instituto de Salud Carlos III, 28029 Madrid, Spain
Servicio de Microbiología, Hospital Universitario Miguel Servet, 3ISS Aragón, 50009 Zaragoza, Spain
Author to whom correspondence should be addressed.
Appl. Sci. 2020, 10(7), 2632;
Received: 10 March 2020 / Revised: 30 March 2020 / Accepted: 31 March 2020 / Published: 10 April 2020
(This article belongs to the Special Issue Tuberculosis Drug Discovery and Development 2019)
In addition to antibiotics, vaccination is considered among the most efficacious methods in the control and the potential eradication of infectious diseases. New safe and effective vaccines against tuberculosis (TB) could be a very important tool and are called to play a significant role in the fight against TB resistant to antimicrobials. Despite the extended use of the current TB vaccine Bacillus Calmette-Guérin (BCG), TB continues to be transmitted actively and continues to be one of the 10 most important causes of death in the world. In the last 20 years, different TB vaccines have entered clinical trials. In this paper, we review the current use of BCG and the diversity of vaccines in clinical trials and their possible indications. New TB vaccines capable of protecting against respiratory forms of the disease caused by sensitive or resistant Mycobacterium tuberculosis strains would be extremely useful tools helping to prevent the emergence of multi-drug resistance. View Full-Text
Keywords: BCG; tuberculosis vaccines; TBVI; EDCTP; IAVI; CTVD BCG; tuberculosis vaccines; TBVI; EDCTP; IAVI; CTVD
Show Figures

Figure 1

MDPI and ACS Style

Martin, C.; Aguilo, N.; Marinova, D.; Gonzalo-Asensio, J. Update on TB Vaccine Pipeline. Appl. Sci. 2020, 10, 2632.

AMA Style

Martin C, Aguilo N, Marinova D, Gonzalo-Asensio J. Update on TB Vaccine Pipeline. Applied Sciences. 2020; 10(7):2632.

Chicago/Turabian Style

Martin, Carlos; Aguilo, Nacho; Marinova, Dessislava; Gonzalo-Asensio, Jesus. 2020. "Update on TB Vaccine Pipeline" Appl. Sci. 10, no. 7: 2632.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop